Long‐term (6 and 12 months) follow‐up of two prospective, randomized, controlled phase III trials of photodynamic therapy with BF‐200 ALA and methyl aminolaevulinate for the treatment of actinic keratosis
| Autor: | G. Krähn-Senftleben, M. Deichmann, L. Karl, F. Borrosch, F. Hübinger, H. Brüning, Carola Berking, B. Schmitz, D. Gröne, Kristian Reich, G. Pabst, W. Klövekorn, M. Sebastian, M. Tanner, Peter Wolf, R.-M. Szeimies, Hermann Lübbert, Thomas Dirschka, M. Foguet, K. Wernicke-Panten, S. Hahn, Percy Lehmann, M. Moers-Carpi, Günther F.L. Hofbauer, L. Jenne, Matthias Simon, C. Oster-Schmidt, H. Mensing, D. Voss, Uwe Reinhold, Herbert Hönigsmann, P. Radny, R. Dominicus |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Keratosis medicine.medical_treatment Photodynamic therapy Dermatology law.invention Pharmacotherapy Randomized controlled trial Recurrence law medicine Humans Prospective Studies Prospective cohort study Aged Aged 80 and over Photosensitizing Agents business.industry Actinic keratosis Aminolevulinic Acid Middle Aged medicine.disease Long-Term Care Keratosis Actinic Clinical trial Treatment Outcome Photochemotherapy Drug Therapy Combination Female Skin cancer business Follow-Up Studies |
| Zdroj: | British Journal of Dermatology. 168:825-836 |
| ISSN: | 1365-2133 0007-0963 |
| Popis: | Two phase III trials of photodynamic therapy (PDT) with BF-200 ALA, a recently approved nanoemulsion formulation of 5-aminolaevulinic acid (ALA) demonstrated high clearance rates in mild-to-moderate actinic keratosis (AK). The comparison to a registered methyl aminolaevulinate (MAL) cream demonstrated significantly superior total patient clearance rates.To evaluate long-term efficacy and safety of PDT for AK 6 and 12 months after the last PDT with BF-200 ALA, MAL or placebo.The follow-up phase (FUP) was performed with patients of two phase III studies. Both studies compared BF-200 ALA with placebo, one of the studies additionally with MAL. Overall recurrence rates and various subgroups (light source, lesion severity, lesion location, complete responders after first PDT) were assessed 6 and 12 months after the last PDT.Recurrence rates were similar for BF-200 ALA and MAL, with a tendency to lower recurrence rates for BF-200 ALA. The proportion of patients who were fully cleared during PDT and remained completely clear for at least 12 months after PDT were 47% for BF-200 ALA (both studies) and 36% for MAL treatment. The subgroup that was illuminated with narrow wavelength LED lamps reached 69% and 53% for BF-200 ALA (both studies, respectively) and 41% for MAL. No safety concerns were reported.The FUP data confirmed the high efficacy and safety of PDT with BF-200 ALA. The slightly lower recurrence rates after BF-200 ALA treatment compared with MAL treatment enhanced the better treatment outcome due to the significantly superior efficacy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text